Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of VivaGel (SPL7013 Gel) to prevent recurrence of bacterial vaginosis
2014-000694-39Phase 3Completed
- Sponsor
- Starpharma
- Start
- Jul 2014
- Modality
- Peptides, Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in bacterial vaginosis (BV) comparing VivaGel 1% SPL7013 Gel with Placebo HEC gel (2 arms). Primary endpoint: Recurrence of bacterial vaginosis by Week 16. Started Jul 2014; status: completed.
02
Drugs
astodrimer
03
Conditions
bacterial vaginosis (BV)
Beyond the preview
Go deeper on 2014-000694-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-000694-39.